Parcion Private Wealth LLC Sells 134 Shares of Thermo Fisher Scientific Inc. $TMO

Parcion Private Wealth LLC lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 735 shares of the medical research company’s stock after selling 134 shares during the quarter. Parcion Private Wealth LLC’s holdings in Thermo Fisher Scientific were worth $298,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the business. Steel Grove Capital Advisors LLC lifted its position in Thermo Fisher Scientific by 4.1% during the second quarter. Steel Grove Capital Advisors LLC now owns 757 shares of the medical research company’s stock valued at $307,000 after purchasing an additional 30 shares during the last quarter. Brookstone Capital Management lifted its holdings in shares of Thermo Fisher Scientific by 9.8% in the 2nd quarter. Brookstone Capital Management now owns 8,923 shares of the medical research company’s stock worth $3,618,000 after acquiring an additional 795 shares during the last quarter. Boit C F David lifted its holdings in shares of Thermo Fisher Scientific by 22.6% in the 2nd quarter. Boit C F David now owns 2,715 shares of the medical research company’s stock worth $1,101,000 after acquiring an additional 500 shares during the last quarter. Cullen Frost Bankers Inc. lifted its holdings in shares of Thermo Fisher Scientific by 5.7% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 32,789 shares of the medical research company’s stock worth $13,295,000 after acquiring an additional 1,754 shares during the last quarter. Finally, Argonautica Private Wealth Management Inc. bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth about $337,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.9%

Shares of TMO opened at $568.42 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market capitalization of $214.64 billion, a price-to-earnings ratio of 32.88, a PEG ratio of 3.22 and a beta of 0.77. The company has a 50-day moving average of $500.65 and a 200 day moving average of $451.30. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on TMO shares. William Blair started coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an “outperform” rating for the company. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a report on Thursday, July 24th. JPMorgan Chase & Co. lifted their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Finally, Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $581.63.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.